跳至主要内容
临床试验/EUCTR2017-004642-20-ES
EUCTR2017-004642-20-ES进行中(未招募)1 期

Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder

Idorsia Pharmaceuticals Ltd0 个研究点目标入组 930 人开始时间: 2018年6月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
930

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Signed informed consent prior to any study-mandated procedure;
  • - Male or female aged > o = 18 years;
  • - Insomnia disorder according to DSM-5 criteria;
  • - Insomnia Severity Index score > or = 15;
  • - Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography;
  • - Women of childbearing potential must have a negative and urine pregnancy test and use the contraception scheme up to at least 30 days after last study treatment intake.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 540
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 360

排除标准

  • - Body mass index below 18.5 or above 40.0 kg/m2;
  • - Any lifetime history of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, narcolepsy, or apnea/hypopnea;
  • - Cognitive behavioral therapy (CBT) for any indication is allowed, only, if CBT started at least 1 month prior to Visit 3 and the subject agrees to continue this CBT throughout the study;
  • - Self-reported usual daytime napping > o = 1 hour per day and > o = 3 days per week;
  • - Acute or unstable psychiatric conditions diagnosed by the Mini International Neuropsychiatric Interview;
  • - Mini Mental State Examination (MMSE) score < 25 in subjects > o = 50 years;
  • - For female subjects: pregnant, lactating or planning to become pregnant during projected duration of the study;
  • - History or clinical evidence of any disease or medical condition or
  • treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
  • - Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

研究者

相似试验

Study to assess the efficacy and safety of... | 临床试验